New PET tracer could spot hidden prostate cancer spread

NCT ID NCT03173924

Ongoing Diagnosis Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Aug 07, 2026 · Updated 2 times

Summary

This study compares a new radioactive tracer called 18F-DCFPyL with standard tracers to see if it can better detect where prostate cancer has spread in the body. About 96 men with metastatic prostate cancer will receive both tracers and undergo PET/CT scans. The goal is to measure how accurately the new tracer identifies cancer sites, which could improve treatment planning.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 18F-DCFPyL (a radioactive tracer for PET scans)
What this could lead to: If successful, this could lead to a more accurate imaging method for finding prostate cancer spread, helping doctors choose better treatments.
What could go wrong: This is a small, early-phase study focused on imaging accuracy, not treatment. The new tracer may not prove significantly better than existing methods.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

disease metastatic prostate carcinoma prostate cancer prostate neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC PROSTATE CANCER PROSTATE CANCER PROSTATE NEOPLASMS PROSTATIC CANCER PROSTATIC NEOPLASMS

Contacts and locations

Locations

National Institutes of Health Clinical Center

Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.